Galectin-3 as a Marker of Subclinical Inflammation in FMF

Assessment of Serum Galectin-3 Level as an Indicator of Subclinical Inflammation in Patients With Familial Mediterranean Fever

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06451471

Enrollment

154

Registered

2024-06-11

Start date

2021-05-01

Completion date

2022-11-01

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ailesel Akdeniz Ateşi

Keywords

GALEKTİN-3, Subclinical Inflammation

Brief summary

The goal of this observational study is to learn about the relationship between serum Galectin-3 levels and subclinical inflammation in patients with Familial Mediterranean Fever (FMF). The main questions it aims to answer are: * Are serum Galectin-3 levels higher in FMF patients compared to healthy controls? * Is there a positive correlation between serum Galectin-3 levels and Serum Amyloid A (SAA) protein levels in FMF patients? Participants will: * Provide blood samples to measure serum Galectin-3 and SAA levels. * Complete a sociodemographic and clinical data form. * Fill out the FMF Quality of Life (QoL) scale. Researchers will compare FMF patients and healthy controls to see if there are significant differences in serum Galectin-3 levels and to determine the correlation between Galectin-3 and SAA protein levels in FMF patients.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* for the Patient Group: 1. Aged between 18 and 65 years, 2. Able to provide written informed consent for the study, 3. Literate, 4. Diagnosed with Familial Mediterranean Fever (FMF) according to the Tel Hashomer criteria and not currently experiencing an attack (with at least 15 days since the last attack). * Inclusion Criteria for the Healthy Control Group:  1. Aged between 18 and 65 years, 2. Able to provide written informed consent for the study, 3. Literate.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Serum Galectin-3 Levels	2022	Comparison of serum Galectin-3 levels between FMF patients and healthy controls to determine if there is a significant difference.

Secondary

Measure	Time frame	Description
Serum Amyloid A (SAA) Levels	2022	Measurement of SAA levels in both FMF patients and healthy controls.
Correlation Analysis	2022	Determination of the correlation between serum Galectin-3 levels and SAA levels in FMF patients.
Clinical Variables	2022	Analysis of the relationship between Galectin-3/SAA levels and clinical variables such as age, BMI, disease duration, and frequency of FMF attacks.

Countries

Turkey (Türkiye)

Outcome results